<DOC>
	<DOCNO>NCT00332839</DOCNO>
	<brief_summary>Calcineurin inhibitor ( CNI ) , potent immunosuppressive drug use kidney transplant recipient prevent graft rejection , may cause renal impairment . The aim study ass whether CNI-free regimen enteric-coated mycophenolate sodium everolimus safe well tolerated standard regimen consist enteric-coated mycophenolate sodium cyclosporine microemulsion without compromise therapeutic efficacy result improved renal function .</brief_summary>
	<brief_title>Comparison CNI-based Regimen Versus CNI-free Regimen Kidney Transplant Recipients .</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Males female , age &gt; 18 year , Maintenance renal transplant recipient least 6 month posttransplantation , Patients serum creatinine &lt; 2,5 mg/dL stable least three month ( accord investigator ) , Females capable become pregnant negative serum pregnancy test within seven day prior baseline , required practice approve method birth control duration study period six week follow discontinuation study medication , even history infertility , Patients receive Myfortic® ( Myfortic dose . 720 mg/d ) Sandimmun® Optoral without corticosteroid part immunosuppressive regimen least 1 month baseline ; More one previous renal transplantation , Multiorgan recipient ( e.g. , kidney pancreas ) previous transplant organ , different kidney , Patient proteinuria &gt; 1000 mg/day baseline , Hypersensitivity Certican® , Sandimmun® Optoral , Prograf® , mycophenolic acid , component formulation , Patients receive investigational drug within four week prior baseline , Severe rejection ( ≥ Banff II acute rejection ) , recurrent acute rejection , steroid resistant rejection within six month enrollment , Thrombocytopenia ( platelet &lt; 100,000/mm³ ) , absolute neutrophil count &lt; 1,500/mm³ leukopenia ( leukocytes &lt; 4,000/mm³ ) , hemoglobin &lt; 8 g/dL , Abnormal physical laboratory finding clinical significance within two week study inclusion investigator 's discretion would interfere objective study , Symptoms significant somatic mental illness . Inability cooperate communicate investigator , patient unlikely comply study requirement , unable give inform consent , History malignancy last five year , except squamous basal cell carcinoma skin , Patients HIV positive , hepatitis C , hepatitis B surface antigen positiveEvidence severe liver disease ( include abnormal liver enzyme profile , i.e . aspartate transaminase ( AST ) , alanine aminotransferase ( ALT ) total bilirubin &gt; 3 time upper limit normal ( ULN ) , Females childbearing potential planning become pregnant , pregnant lactate and/or unwilling use effective mean contraception , Presence clinically significant infection require continued therapy , severe diarrhea , active peptic ulcer disease uncontrolled diabetes mellitus opinion investigator would interfere appropriate conduct study , Evidence drug alcohol abuse Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>enteric-coated mycophenolate sodium , everolimus , CNI-free regimen</keyword>
</DOC>